BRIEF published on 04/22/2026 at 22:05, 14 days 4 hours ago Inventiva strengthens its leadership for phase 3 of lanifibranor Appointment Biopharmaceutical Direction Phase 3 Lanifibranor
BRIEF published on 04/22/2026 at 22:05, 14 days 4 hours ago Inventiva Bolsters Executive Team as It Nears Key Phase 3 Data Milestone Phase 3 Trial Lanifibranor Leadership Expansion MASH Treatment Inventiva Biopharmaceutical
PRESS RELEASE published on 04/22/2026 at 22:00, 14 days 4 hours ago Inventiva Strengthens Leadership Team Ahead of Expected Phase 3 Data Readout of Lanifibranor Inventiva strengthens leadership team with new key hires for lanifibranor Phase 3 data readout, bolstering expertise in finance, legal, and HR to drive growth and commercialization Growth Leadership Team Phase 3 Inventiva Lanifibranor
BRIEF published on 04/08/2026 at 22:05, 28 days 4 hours ago Inventiva Submits 2025 Financial Reports to AMF and SEC Inventiva 2025 Financial Reports MASH Treatments Biopharmaceutical Developments AMF And SEC Filings
BRIEF published on 04/08/2026 at 22:05, 28 days 4 hours ago Inventiva files its Universal Registration Document and its 2025 Annual Report Annual Report Biopharmaceutical Registration Document Inventiva MASH
PRESS RELEASE published on 04/08/2026 at 22:00, 28 days 4 hours ago Inventiva announces filing of its 2025 Universal Registration Document and 2025 Annual Report on Form 20-F Inventiva files 2025 Universal Registration Document and Annual Report on Form 20-F with AMF and SEC, focusing on MASH therapies Biopharmaceutical 2025 Filing Inventiva MASH
BRIEF published on 04/02/2026 at 15:55, 1 month 4 days ago JP Morgan Chase & Co. crosses the thresholds for participation in INVENTIVA Voting Rights Threshold Crossing JP Morgan Inventiva Equity Swap
BRIEF published on 03/30/2026 at 22:16, 1 month 7 days ago Inventiva Announces 2025 Financial Results and Business Update Public Offering Cash Reserves Inventiva Lanifibranor 2025 Financial Results
PRESS RELEASE published on 03/30/2026 at 22:11, 1 month 7 days ago Inventiva reports 2025 full year results and provides a business update Inventiva reports 2025 full year results with €4.5 million revenues, provides business update on strategic pipeline, clinical trials, and financial performance Financial Performance Business Update Clinical Trials Inventiva 2025 Results
BRIEF published on 03/23/2026 at 22:05, 1 month 14 days ago Inventiva Announces Schedule for 2025 Financial Results Financial Results Conference Call Biopharmaceutical Inventiva MASH
Published on 05/07/2026 at 02:00, 16 minutes ago Lobe Sciences Ltd. Announces Participation in the D. Boral Capital Global Conference in New York
Published on 05/06/2026 at 23:30, 2 hours 46 minutes ago Stabilis Solutions Announces First Quarter 2026 Results
Published on 05/06/2026 at 23:05, 3 hours 11 minutes ago Zomedica Announces Record First Quarter Revenue of $8.8 Million, Reflecting 35% Annual Growth; and $47.5 Million in Liquidity
Published on 05/06/2026 at 23:00, 3 hours 16 minutes ago Green Bridge Metals Strengthens Technical and Strategic Team as 2026 Work Programs Advance
Published on 05/06/2026 at 22:10, 4 hours 6 minutes ago Banyan Gold Announces Closing of $46.5 Million Private Placement
Published on 05/07/2026 at 00:47, 1 hour 29 minutes ago Blue Cap AG expands portfolio through the acquisition of Janoschka AG
Published on 05/07/2026 at 00:43, 1 hour 32 minutes ago EQS-Adhoc: Blue Cap AG Acquires Janoschka AG and Adjusts Forecast Due to Transaction
Published on 05/06/2026 at 20:32, 5 hours 44 minutes ago EQS-Adhoc: Kontron AG: ADHOC Kontron AG / Potential Public Takeover Bid by Ennoconn Corporation
Published on 05/06/2026 at 20:22, 5 hours 54 minutes ago EQS-Adhoc: ams-OSRAM AG: ams OSRAM delivers strong Q1 results, enters AI market through a development agreement with a leading AI photonics customer and sees path to positive Free Cash Flow in 2027
Published on 05/06/2026 at 19:18, 6 hours 58 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 05/06/2026 at 18:00, 8 hours 15 minutes ago Access to information in respect of the General Shareholders’ Meeting to be held on June 4, 2026
Published on 05/06/2026 at 18:00, 8 hours 16 minutes ago Information concerning the total number of voting rights and shares in the share capital as of April 30, 2026
Published on 05/06/2026 at 17:45, 8 hours 31 minutes ago Information concerning the total number of voting rights and shares 2026 04 30
Published on 05/06/2026 at 17:45, 8 hours 31 minutes ago Declaration of voting rights at the end of April 2026
Published on 05/06/2026 at 17:45, 8 hours 31 minutes ago Accor - Information regarding availability and consultation of preparatory documents - Shareholders' Meeting of May 27, 2026
